Therefore, this studies demonstrates that EPHB4 targeted therapy may be capable of changing the prostate tumor microenvironment from “cold to “hot’, thereby increase sensitivity to immune checkpoint inhibitor therapy. The gene discussed is EPHB4; the disease is prostate neoplasm.